Literature DB >> 23725617

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.

Daniel M Rose, A Bruce Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23725617     DOI： 10.1164/rccm.201204-0690LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Williamson Z Bradford; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; David Kardatzke; Talmadge E King; Lisa H Lancaster; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Jeffrey J Swigris; Paul W Noble
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Works in Progress: Using Administrative Data to Estimate the Prevalence of Progressive Fibrosing Interstitial Lung Disease.

Authors:  Willis S Bowman; Timothy Dempsey
Journal:  Ann Am Thorac Soc       Date:  2022-07

3.  Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Authors:  Thomas Bahmer; Anne-Marie Kirsten; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Marco Gramm; Simone Hummler; Eva Brunnemer; Michael Kreuter; Henrik Watz
Journal:  BMC Pulm Med       Date:  2017-07-25       Impact factor: 3.317

4.  Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.

Authors:  Louise A Organ; Anne-Marie R Duggan; Eunice Oballa; Sarah C Taggart; Juliet K Simpson; Arthur R Kang'ombe; Rebecca Braybrooke; Philip L Molyneaux; Bernard North; Yakshitha Karkera; Diana J Leeming; Morten A Karsdal; Carmel B Nanthakumar; William A Fahy; Richard P Marshall; R Gisli Jenkins; Toby M Maher
Journal:  Respir Res       Date:  2019-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.